

Sandro Mazzaferro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8651185/publications.pdf>

Version: 2024-02-01

118
papers

2,908
citations

147801

31
h-index

197818

49
g-index

119
all docs

119
docs citations

119
times ranked

3176
citing authors

#	ARTICLE	IF	CITATIONS
1	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 427-436.	11.4	125
2	Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 2294-2302.	0.7	120
3	Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1672-1679.	0.7	118
4	European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4â€“G5D. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 42-59.	0.7	107
5	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1815-1820.	0.7	103
6	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 319-331.	11.4	102
7	Vitamin D, a modulator of musculoskeletal health in chronic kidney disease. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2017, 8, 686-701.	7.3	84
8	Progression of Coronary Artery Calcification in Renal Transplantation and the Role of Secondary Hyperparathyroidism and Inflammation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 685-690.	4.5	82
9	The Risk of Chronic Kidney Disease Associated with Urolithiasis and its Urological Treatments: A Review. <i>Journal of Urology</i> , 2017, 198, 268-273.	0.4	78
10	Vascular Calcification and Uremia: What Do We Know?. <i>American Journal of Nephrology</i> , 2008, 28, 339-346.	3.1	72
11	Obesity and kidney stone disease: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2018, 70, 393-400.	3.9	69
12	Soluble Klotho Serum Levels in Chronic Kidney Disease. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-8.	1.5	67
13	Valvular heart disease and calcification in CKD: more common than appreciated. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2046-2053.	0.7	62
14	Sarcopenia and cardiovascular risk indices in patients with chronic kidney disease on conservative and replacement therapy. <i>Nutrition</i> , 2019, 62, 108-114.	2.4	56
15	When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 612-625.	1.6	53
16	Pro: Cardiovascular calcifications are clinically relevant. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 345-351.	0.7	53
17	VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3588-3594.	0.7	52
18	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1211-1219.	0.7	52

#	ARTICLE	IF	CITATIONS
19	Serum Levels of Calcification Inhibition Proteins and Coronary Artery Calcium Score: Comparison between Transplantation and Dialysis. <i>American Journal of Nephrology</i> , 2007, 27, 75-83.	3.1	51
20	Vitamin D Metabolites and/or Analogs: Which D for Which Patient?. <i>Current Vascular Pharmacology</i> , 2014, 12, 339-349.	1.7	50
21	Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. <i>Calcified Tissue International</i> , 2018, 103, 111-124.	3.1	45
22	Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone. <i>Osteoporosis International</i> , 2002, 13, 171-175.	3.1	44
23	News on Biomarkers in CKD&€MBD. <i>Seminars in Nephrology</i> , 2014, 34, 598-611.	1.6	44
24	Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative“a position paper. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1608-1613.	0.7	41
25	Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQITM ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2319-2323.	0.7	40
26	Bone GLA protein in predialysis chronic renal failure. Effects of 1,25(OH)2D3 administration in a long-term follow-up. <i>Kidney International</i> , 1985, 28, 783-790.	5.2	39
27	Procollagen Type I C-Terminal Extension Peptide in Predialysis Chronic Renal Failure. <i>American Journal of Nephrology</i> , 1992, 12, 246-251.	3.1	39
28	Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment. <i>Life</i> , 2021, 11, 419.	2.4	38
29	Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. <i>American Journal of Kidney Diseases</i> , 2013, 62, 984-992.	1.9	34
30	Morphometric X-ray absorptiometry in the assessment of vertebral fractures in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 466-471.	0.7	33
31	The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 402-407.	0.7	33
32	Calcitriol/calcifediol ratio: An indicator of vitamin D hydroxylation efficiency?. <i>BBA Clinical</i> , 2015, 3, 251-256.	4.1	33
33	The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease. <i>Current Vascular Pharmacology</i> , 2010, 8, 404-411.	1.7	31
34	Secondary Hyperparathyroidism in Chronic Dialysis Patients: Results of the Italian FARO Survey on Treatment and Mortality. <i>Blood Purification</i> , 2011, 32, 124-132.	1.8	30
35	Fibroblast Growth Factor 23: Mineral Metabolism and Beyond. <i>Contributions To Nephrology</i> , 2017, 190, 83-95.	1.1	30
36	The bone and the kidney. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 95-102.	3.0	29

#	ARTICLE	IF	CITATIONS
37	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
38	Changes in bone turnover after parathyroidectomy in dialysis patients: role of calcitriol administration. Nephrology Dialysis Transplantation, 2000, 15, 877-882.	0.7	28
39	Bone Metabolism and Its Assessment in Renal Failure. Nephron, 1994, 67, 383-401.	1.8	27
40	Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate. Histopathology, 2001, 38, 571-583.	2.9	27
41	Vitamin D in patients with chronic kidney disease: a position statement of the Working Group on Trace Elements and Mineral Metabolism of the Italian Society of Nephrology. Journal of Nephrology, 2016, 29, 305-328.	2.0	26
42	Bone, inflammation and the bone marrow niche in chronic kidney disease: what do we know?. Nephrology Dialysis Transplantation, 2018, 33, 2092-2100.	0.7	26
43	Bone, inflammation and chronic kidney disease. Clinica Chimica Acta, 2020, 506, 236-240.	1.1	26
44	Prospective Evaluation of Total Parathyroidectomy and Autotransplantation for the Treatment of Secondary Hyperparathyroidism. Archives of Surgery, 1999, 134, 68.	2.2	25
45	Vitamin D: a dynamic molecule. How relevant might the dynamism for a vitamin be?. Nephrology Dialysis Transplantation, 2016, 31, 23-30.	0.7	25
46	Effects of Haemodialysis Session on Plasma Beta-Endorphin, ACTH and Cortisol in Patients with End-Stage Renal Disease. Scandinavian Journal of Urology and Nephrology, 1996, 30, 399-402.	1.4	23
47	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, 30, 698-700.	0.7	23
48	Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS ONE, 2017, 12, e0178637.	2.5	22
49	Procollagen Type 1 C-Terminal Extension Peptide Serum Levels following Parathyroidectomy in Hyperparathyroid Patients. American Journal of Nephrology, 1994, 14, 106-112.	3.1	21
50	Calcific Uremic Arteriopathy: A Call for Action. Seminars in Nephrology, 2014, 34, 641-647.	1.6	21
51	Achievement of NKF/K-DOQI Recommended Target Values for Bone and Mineral Metabolism in Incident Hemodialysis Patients: Results of the FARO-2 Cohort. Blood Purification, 2014, 38, 37-45.	1.8	20
52	Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis. Journal of Translational Medicine, 2019, 17, 388.	4.4	19
53	Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnesium Research, 2016, 29, 126-140.	0.5	18
54	Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1269-1280.	4.5	17

#	ARTICLE	IF	CITATIONS
55	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	1.9	17
56	Inflammation, Oxidative Stress, and Bone in Chronic Kidney Disease in the Osteoimmunology Era. <i>Calcified Tissue International</i> , 2021, 108, 452-460.	3.1	17
57	Distinct impact of vitamin D insufficiency on calcitriol levels in chronic renal failure and renal transplant patients: a role for FGF23. <i>Journal of Nephrology</i> , 2012, 25, 1108-1118.	2.0	16
58	Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion. <i>Endocrine</i> , 2018, 59, 242-259.	2.3	15
59	Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. <i>Journal of Nephrology</i> , 2011, 24, 225-235.	2.0	15
60	Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2859-2865.	0.7	14
61	Vascular calcification, bone and mineral metabolism after kidney transplantation. <i>World Journal of Transplantation</i> , 2015, 5, 222.	1.6	14
62	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 567-571.	2.9	12
63	Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study. <i>BMC Nephrology</i> , 2015, 16, 11.	1.8	12
64	Î±-lipoic acid in patients with autosomal dominant polycystic kidney disease. <i>Nutrition</i> , 2020, 71, 110594.	2.4	12
65	Positioning novel biologicals in CKD-mineral and bone disorders. <i>Journal of Nephrology</i> , 2017, 30, 689-699.	2.0	11
66	Prebiotic Therapy with Inulin Associated with Low Protein Diet in Chronic Kidney Disease Patients: Evaluation of Nutritional, Cardiovascular and Psychocognitive Parameters. <i>Toxins</i> , 2020, 12, 381.	3.4	11
67	The Role of Diet in Bone and Mineral Metabolism and Secondary Hyperparathyroidism. <i>Nutrients</i> , 2021, 13, 2328.	4.1	11
68	Procollagen type 1 C-terminal extension peptide, PTH and 1,25(OH)2D3 in chronic renal failure. <i>Bone</i> , 1993, 14, 415-420.	2.9	9
69	Focus on the Possible Role of Dietary Sodium, Potassium, Phosphate, Magnesium, and Calcium on CKD Progression. <i>Journal of Clinical Medicine</i> , 2021, 10, 958.	2.4	9
70	Time for Revival of Bone Biopsy with Histomorphometric Analysis in Chronic Kidney Disease (CKD): Moving from Skepticism to Pragmatism. <i>Nutrients</i> , 2022, 14, 1742.	4.1	8
71	Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. <i>Journal of Medical Economics</i> , 2012, 15, 1110-1117.	2.1	7
72	Oxygen Extraction Ratio (OER) as a Measurement of Hemodialysis (HD) Induced Tissue Hypoxia: A Pilot Study. <i>Scientific Reports</i> , 2018, 8, 5655.	3.3	7

#	ARTICLE	IF	CITATIONS
73	On the role of skin biopsy in the diagnosis of calcific uremic arteriolopathy: a case-based discussion. <i>Journal of Nephrology</i> , 2020, 33, 859-865.	2.0	7
74	Association between Multidimensional Prognostic Index and Hospitalization and Mortality among Older Adults with Chronic Kidney Disease on Conservative or on Replacement Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3965.	2.4	7
75	Cholemic Nephropathy as Cause of Acute and Chronic Kidney Disease. Update on an Under-Diagnosed Disease. <i>Life</i> , 2021, 11, 1200.	2.4	7
76	Effects of vitamin D on parathyroid hormone and clinical outcomes in peritoneal dialysis: a narrative review. <i>Journal of Nephrology</i> , 2014, 27, 483-494.	2.0	6
77	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 357-357.	0.7	6
78	Treatment of Cardiovascular Calcification in Uremia. <i>Current Vascular Pharmacology</i> , 2011, 9, 741-749.	1.7	6
79	Ionised and total serum magnesium in renal transplant patients. <i>Journal of Nephrology</i> , 2002, 15, 275-80.	2.0	6
80	Evaluation of osteoblastic activity by morphometric comparison of alkaline phosphatase cytochemistry vs. tetracycline fluorescence. <i>Bone</i> , 1993, 14, 321-326.	2.9	5
81	Extent of alkaline phosphatase cytochemistry vs. extent of tetracycline fluorescence in the evaluation of histodynamic variables of bone formation. <i>Bone</i> , 1995, 16, 493-498.	2.9	5
82	Changes in adrenomedullin plasma concentrations during haemodialysis in patients with chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 1999, 14, 519-520.	0.7	5
83	Multicenter study on parathyroidectomy (PTX) in Italy: preliminary results. <i>Journal of Nephrology</i> , 2018, 31, 767-773.	2.0	5
84	Bone biopsy in chronic kidney disease: still neglected and in need of revitalization. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 202-204.	0.7	5
85	Circannual versus seasonal variations of longitudinally sampled 25-hydroxycholecalciferol serum levels. <i>Biochemical Medicine</i> , 1984, 32, 22-29.	0.5	4
86	Direct bone effects of calcimimetics in chronic kidney disease?. <i>Kidney International</i> , 2019, 95, 1012-1014.	5.2	4
87	Renal resistive index in IgA nephropathy and renal scleroderma vasculopathy. <i>Microvascular Research</i> , 2021, 133, 104095.	2.5	4
88	Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot Study. <i>Current Vascular Pharmacology</i> , 2021, 19, 556-564.	1.7	4
89	Clinical impact of vitamin D hydroxylation efficiency. <i>Minerva Medica</i> , 2019, 110, 259-262.	0.9	4
90	New insights into the role of calcium-sensing receptor activation. <i>Journal of Nephrology</i> , 2011, 24, 38-41.	2.0	4

#	ARTICLE	IF	CITATIONS
91	Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014, 8, 1.	1.8	3
92	Bone in CKD: why the ERA EDTA CKD-MBD working group organized a dedicated meeting?. <i>Journal of Nephrology</i> , 2017, 30, 621-622.	2.0	3
93	Ischemic Nephropaty: The Role of the Renal Artery Stenosis Revascularization on Renal Stem Cells. <i>Medicina (Lithuania)</i> , 2021, 57, 944.	2.0	3
94	PIXE technique for calcium analysis of human bone. <i>Biological Trace Element Research</i> , 1986, 10, 123-127.	3.5	2
95	Autonomic neuropathy and secondary hyperparathyroidism in uremia. <i>Journal of the Autonomic Nervous System</i> , 1990, 30, S149-S151.	1.9	2
96	Vitamin D Receptor Activators. <i>International Journal of Artificial Organs</i> , 2009, 32, 101-107.	1.4	2
97	Calciphylaxis: a conundrum for patients and nephrologists?. <i>Journal of Nephrology</i> , 2019, 32, 677-680.	2.0	2
98	A new technique for measuring fistula flow using venous blood gas oxygen saturation in patients with a central venous catheter. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 184-187.	2.9	2
99	Oxygen extraction ratio to identify patients at increased risk of intradialytic hypotension. <i>Scientific Reports</i> , 2021, 11, 4801.	3.3	2
100	Waves of infection and waves of communication: the importance of sharing in the era of Covid-19. <i>Journal of Nephrology</i> , 2021, 34, 633-636.	2.0	2
101	Results of the implementation of a triage system of vascular access performance in haemodialysis patients: experience of a single dialysis centre. <i>Journal of Nephrology</i> , 2022, 35, 969-976.	2.0	2
102	Biologic effect of 1,24(R)(OH)2D3 versus 1,25(OH)2D3 administration in chronic renal failure. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1992, 42, 823-829.	2.5	1
103	Safe Employment of Recombinant Human Erythropoietin in Pregnancy in Two Anuric Patients on Regular Dialysis Treatment. <i>Renal Failure</i> , 1995, 17, 73-76.	2.1	1
104	How Can We Assess Bone Resorption in Uremia?. <i>Nephron Clinical Practice</i> , 2004, 98, c103-c104.	2.3	1
105	Adult Patients Affected by Cystic Fibrosis in Therapy with Cystic Fibrosis Transmembrane Regulator Modulators and Lung Transplant: Renal Function, Metabolic and Nutritional Status. <i>Journal of Nutrition and Metabolism</i> , 2020, 2020, 1-8.	1.8	1
106	Dialysate calcium concentration during calcimimetic treatment: a neglected issue. <i>Journal of Nephrology</i> , 2021, 34, 19-22.	2.0	1
107	Interaction Between Vitamin D and Calcimimetics in Chronic Kidney Disease. , 2016, , 537-562.		1
108	Diastolic Pressure and ACR Are Modifiable Risk Factors of Arterial Stiffness in T2DM Without Cardiovascular Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3857-e3865.	3.6	1

#	ARTICLE	IF	CITATIONS
109	Calcium density measurement in histological samples of trabecular bone of normal subjects: Relationship with aging. Archives of Gerontology and Geriatrics, 1992, 15, 27-35.	3.0	0
110	Editorial (Thematic issue :VITAMIN D THERAPY: AN UPDATE Available Experimental and Clinical Evidences) Tj ETQq0 0 0 rgBT /Overlock I 12, 271-271.	1.7	0
111	A new Hyperphosphatemia Drug. Giornale De Tecniche Nefrologiche & Dialitiche, 2016, 28, 12-15.	0.1	0
112	MO959KIDNEY TRANSPLANT TRANSITION FROM PEDIATRIC TO ADULT FACILITY CARE: DIFFICULTIES AND RISK FACTORS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
113	MO420ROLE OF IL-6 ON ACUTE KIDNEY INJURY (AKI) DEVELOPMENT AFTER LIVER TRANSPLANTATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
114	A simple visual clot scoring system allows reduction of the dose of low molecular weight heparin in hemodialysis. Hemodialysis International, 2021, 25, 560-562.	0.9	0
115	Renal Diseases and Skeletal Health. , 2018, , 183-209.		0
116	Parathyroidectomy in Chronic Kidney Disease. , 2020, , 175-185.		0
117	MO792: Validation and Applicability of an Innovative Monitoring System for Vascular Access in Haemodialysisâ€”A Multicentre Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
118	MO545: Estimated Proximal Tubule Fluid Phosphate Concentration: An Early Marker of CKD-MBD?. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0